Concepedia

R. Angelo de Claro

RA

Statistics

Publications

27

Citations

1.6K

H-Index

19

Active since

2004

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Amgen (United States)

University of Washington

Moffitt Cancer Center

R. Angelo de Claro is an author at United States Food and Drug Administration specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2004–2024

27

Publications

27

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro et al. · Clinical Cancer Research · 2018 · 225 citations

, , +15

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 209 citations

, , +17

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang et al. · The Oncologist · 2017 · 190 citations

, , +14

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun et al. · Clinical Cancer Research · 2015 · 165 citations

, , +17

FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma

Nicholas C. Richardson, Yvette L. Kasamon, Haiyan Chen et al. · The Oncologist · 2019 · 81 citations · Full text

, , +15

1–5 of 27